Recent News

• 08.28.2025 - Viking Therapeutics to Participate at Upcoming Investor Conferences
• 08.19.2025 - Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity
• 07.23.2025 - Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 07.16.2025 - Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025
• 06.25.2025 - Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735
• 05.28.2025 - Viking Therapeutics to Participate at Upcoming Investor Conferences

Recent Filings

• 08.19.2025 - EX-99.1 EX-99.1
• 08.19.2025 - 8-K Current report
• 08.06.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.23.2025 - EX-99.1 EX-99.1
• 07.23.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.23.2025 - 8-K Current report
• 07.03.2025 - 144 Report of proposed sale of securities
• 07.03.2025 - 144 Report of proposed sale of securities
• 07.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.03.2025 - 4 Statement of changes in beneficial ownership of securities